Skip to main content

Advertisement

SpringerLink
Log in

Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies

  • Stroke (B. Ovbiagele, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The benefit of using antiplatelet monotherapy in acute ischemic stroke and secondary stroke prevention is well established. In the last few years, several large randomized trials showed that the use of short-term dual antiplatelet therapy in particular stroke subtypes may reduce the risk of recurrent ischemic events. The aim of this article is to provide a critical analysis of the current evidence and recommendations for the use of antiplatelet agents for stroke prevention.

Recent Findings

Long-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for secondary stroke prevention in patients with noncardioembolic ischemic stroke. Short-term dual antiplatelet therapy with aspirin and clopidogrel is superior to antiplatelet monotherapy in secondary stroke prevention when used in patients with mild noncardioembolic stroke or high-risk transient ischemic attack. Dual therapy, however, is associated with an increased risk of major bleeding, particularly when the treatment is extended for greater than 30 days. Similarly, aspirin plus ticagrelor is superior to aspirin monotherapy for the prevention of recurrent ischemic stroke, although this combination is associated with a higher risk of hemorrhagic complications when compared to other dual antiplatelet regimens. Among patients who carry CYP2C19 genetic polymorphisms associated with a slow bioactivation of clopidogrel, short-term treatment with aspirin plus ticagrelor is superior to aspirin plus clopidogrel for the reduction of recurrent stroke; however, the use of ticagrelor is associated with a higher risk of any bleeding. In patients with symptomatic intracranial stenosis, aggressive medical management in addition to dual antiplatelet therapy up to 90 days is recommended.

Summary

Antiplatelet therapy has an essential role in the management of ischemic stroke. The specific antiplatelet regimen should be individualized based on the stroke characteristics, time from symptom onset, and patient-specific predisposition to develop hemorrhagic complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–639.

    Article  PubMed  Google Scholar 

  2. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.

    Article  PubMed  Google Scholar 

  3. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.

    Article  CAS  PubMed  Google Scholar 

  5. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40(7):607–17.

    Article  CAS  PubMed  Google Scholar 

  6. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–832.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, Coker TR, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(16):1577–84.

    Article  PubMed  Google Scholar 

  8. The International Stroke Trial (IST). a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke International Stroke Trial Collaborative Group. Lancet. 1997;349(9065):1569–81.

    Article  Google Scholar 

  9. CAST. randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–9.

    Article  Google Scholar 

  10. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al. Indications for early aspirin use in acute ischemic stroke : a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial On behalf of the CAST and IST collaborative groups. Stroke. 2000;31(6):1240–9.

    Article  CAS  PubMed  Google Scholar 

  11. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333(24):1588–93.

    Article  CAS  PubMed  Google Scholar 

  12. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing. 1986;15(2):84–8.

    Article  CAS  PubMed  Google Scholar 

  13. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke. 2002;33(7):1934–42.

    Article  CAS  PubMed  Google Scholar 

  14. Zinkstok SM, Roos YB. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380(9843):731–7.

    Article  CAS  PubMed  Google Scholar 

  15. Liu J, Hu X, Wang Y, Guan X, Chen J, Liu H. The safety and effectiveness of early anti-platelet therapy after alteplase for acute ischemic stroke: a meta-analysis. J Clin Neurosci. 2021;91:176–82.

    Article  CAS  PubMed  Google Scholar 

  16. Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ, Lee SH. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. Neurology. 2016;87(10):996–1002.

    Article  CAS  PubMed  Google Scholar 

  17. Awtry EH, Loscalzo J. Aspirin Circulation. 2000;101(10):1206–18.

    Article  CAS  PubMed  Google Scholar 

  18. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 2002;324(7329):71–86.

  19. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–467.

    Article  PubMed  Google Scholar 

  20. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51(19):1829–43.

    Article  CAS  PubMed  Google Scholar 

  21. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B. Antiplatelet regimen for patients with breakthrough strokes while on aspirin: a systematic review and meta-analysis. Stroke. 2017;48(9):2610–3.

    Article  PubMed  Google Scholar 

  22. Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20(7):463–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.Lancet. 1996;348(9038):1329-39

  24. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004;35(2):528–32.

    Article  CAS  PubMed  Google Scholar 

  25. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Paciaroni M, Ince B, Hu B, Jeng JS, Kutluk K, Liu L, et al. Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis. Cardiovasc Ther. 2019;2019:1607181.

    Article  PubMed  PubMed Central  Google Scholar 

  27. McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc. 2015;4(6):e001652.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke. 2013;44(6):1717–9.

    Article  CAS  PubMed  Google Scholar 

  29. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135(1):21–33.

    Article  CAS  PubMed  Google Scholar 

  30. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39–46.

    Article  CAS  PubMed  Google Scholar 

  31. The European Stroke Prevention Study (ESPS). Principal end-points The ESPS Group. Lancet. 1987;2(8572):1351–4.

    Google Scholar 

  32. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2 Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.

    Article  CAS  PubMed  Google Scholar 

  33. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665–73.

    Article  CAS  PubMed  Google Scholar 

  34. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008;39(4):1358–63.

    Article  CAS  PubMed  Google Scholar 

  35. Douen AG, Medic S, Sabih M, Pageau N, Shuaib A. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke. J Stroke Cerebrovasc Dis. 2008;17(6):356–9.

    Article  PubMed  Google Scholar 

  36. Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther. 2010;8(2):151–8.

    Article  CAS  PubMed  Google Scholar 

  37. Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, et al. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation. 2016;134(12):861–71.

    Article  CAS  PubMed  Google Scholar 

  38. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35–43.

    Article  CAS  PubMed  Google Scholar 

  39. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Ticagrelor versus aspirin in acute embolic stroke of undetermined source. Stroke. 2017;48(9):2480–7.

    Article  CAS  PubMed  Google Scholar 

  40. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(4):301–10.

    Article  CAS  PubMed  Google Scholar 

  41. Malhotra K, Goyal N, Kasunich AS, Sheth SA, Katsanos AH, Alexandrov AV, et al. Ticagrelor for stroke prevention in patients with vascular risk factors: a systematic review and meta-analysis. J Neurol Sci. 2018;390:212–8.

    Article  CAS  PubMed  Google Scholar 

  42. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36(5):313–20.

    Article  CAS  PubMed  Google Scholar 

  43. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9(4):147–57.

    Article  CAS  PubMed  Google Scholar 

  44. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959–68.

    Article  CAS  PubMed  Google Scholar 

  45. Chai E, Chen J, Li C, Zhang X, Fan Z, Yang S, et al. The efficacy and safety of cilostazol vs. aspirin for secondary stroke prevention: a systematic review and meta-analysis. Front Neurol. 2022;13:814654.

  46. Zhang WH, Cai FF, Wen ZM. Effects of cilostazol on the progression and regression of symptomatic intracranial artery stenosis: it reduces the risk of ischemic stroke. Neural Regen Res. 2015;10(4):667–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Miyamoto S, Ogasawara K, Kuroda S, Itabashi R, Toyoda K, Itoh Y, et al. Japan Stroke Society Guideline 2021 for the Treatment of Stroke. Int J Stroke. 2022:17474930221090347.

  48. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367.

    Article  PubMed  Google Scholar 

  49. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.

    Article  CAS  PubMed  Google Scholar 

  50. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–25.

    Article  PubMed  Google Scholar 

  51. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke. 2011;6(2):164–75.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.

    Article  CAS  PubMed  Google Scholar 

  53. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004;328(7435):326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, et al. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: one-year outcomes. Circulation. 2015;132(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  55. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207–17.

    Article  CAS  PubMed  Google Scholar 

  57. Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, et al. Efficacy and safety of ticagrelor and aspirin in patients with moderate ischemic stroke: an exploratory analysis of the THALES randomized clinical trial. JAMA Neurol. 2021;78(9):1091–8.

    Article  PubMed  Google Scholar 

  58. Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520–30.

    Article  CAS  PubMed  Google Scholar 

  59. Pan Y, Meng X, Jin A, Johnston SC, Li H, Bath PM, et al. Time course for benefit and risk with ticagrelor and aspirin in individuals with acute ischemic stroke or transient ischemic attack who carry CYP2C19 loss-of-function alleles: a secondary analysis of the CHANCE-2 randomized clinical trial. JAMA Neurol. 2022;79(8):739–45.

    Article  PubMed  Google Scholar 

  60. Trifan G, Gorelick PB, Testai FD. Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials. Circulation. 2021;143(25):2441–53.

    Article  PubMed  Google Scholar 

  61. Lun R, Dhaliwal S, Zitikyte G, Roy DC, Hutton B, Dowlatshahi D. Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. JAMA Neurol. 2022;79(2):141–8.

    Article  PubMed  Google Scholar 

  62. Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391(10123):850–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–30.

    Article  CAS  PubMed  Google Scholar 

  64. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38.

    Article  PubMed  Google Scholar 

  65. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867–72.

    Article  PubMed  Google Scholar 

  66. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201.

    Article  CAS  PubMed  Google Scholar 

  67. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–17.

    Article  CAS  PubMed  Google Scholar 

  68. Ntaios G, Pearce LA, Veltkamp R, Sharma M, Kasner SE, Korompoki E, et al. Potential embolic sources and outcomes in embolic stroke of undetermined source in the NAVIGATE-ESUS Trial. Stroke. 2020;51(6):1797–804.

    Article  PubMed  Google Scholar 

  69. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305–16.

    Article  CAS  PubMed  Google Scholar 

  70. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(5):489–97.

    Article  CAS  PubMed  Google Scholar 

  71. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Uchiyama S, Sakai N, Toi S, Ezura M, Okada Y, Takagi M, et al. Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS). Cerebrovasc Dis Extra. 2015;5(1):1–13.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782–6.

    Article  CAS  PubMed  Google Scholar 

  74. Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke. 2011;42(10):2883–90.

    Article  CAS  PubMed  Google Scholar 

  75. Mashour GA, Shanks AM, Kheterpal S. Perioperative stroke and associated mortality after noncardiac, nonneurologic surgery. Anesthesiology. 2011;114(6):1289–96.

    Article  PubMed  Google Scholar 

  76. Spence J, LeManach Y, Chan MTV, Wang CY, Sigamani A, Xavier D, et al. Association between complications and death within 30 days after noncardiac surgery. CMAJ. 2019;191(30):E830–7.

    Article  PubMed  Google Scholar 

  77. Gaudino M, Rahouma M, Di Mauro M, Yanagawa B, Abouarab A, Demetres M, et al. Early versus delayed stroke after cardiac surgery: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(13): e012447.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Sharifpour M, Moore LE, Shanks AM, Didier TJ, Kheterpal S, Mashour GA. Incidence, predictors, and outcomes of perioperative stroke in noncarotid major vascular surgery. Anesth Analg. 2013;116(2):424–34.

    Article  PubMed  Google Scholar 

  79. Macellari F, Paciaroni M, Agnelli G, Caso V. Perioperative stroke risk in nonvascular surgery. Cerebrovasc Dis. 2012;34(3):175–81.

    Article  PubMed  Google Scholar 

  80. Benesch C, Glance LG, Derdeyn CP, Fleisher LA, Holloway RG, Messé SR, et al. Perioperative neurological evaluation and management to lower the risk of acute stroke in patients undergoing noncardiac, nonneurological surgery: a scientific statement from the American Heart Association/American Stroke Association. Circulation. 2021;143(19):e923–46.

    Article  CAS  PubMed  Google Scholar 

  81. Peguero JG, Issa O, Podesta C, Elmahdy HM, Santana O, Lamas GA. Usefulness of the CHA2DS2VASc score to predict postoperative stroke in patients having cardiac surgery independent of atrial fibrillation. Am J Cardiol. 2015;115(6):758–62.

    Article  PubMed  Google Scholar 

  82. van Diepen S, Youngson E, Ezekowitz JA, McAlister FA. Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery? Am Heart J. 2014;168(1):60-7.e5.

    Article  PubMed  Google Scholar 

  83. Oscarsson A, Gupta A, Fredrikson M, Järhult J, Nyström M, Pettersson E, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104(3):305–12.

    Article  CAS  PubMed  Google Scholar 

  84. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217–20.

    Article  PubMed  Google Scholar 

  85. García Rodríguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011;76(8):740–6.

    Article  PubMed  Google Scholar 

  86. Ostergaard K, Pottegård A, Hallas J, Bak S, dePont CR, Gaist D. Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death: a cohort study. Neuroepidemiology. 2014;43(1):57–64.

    Article  PubMed  Google Scholar 

  87. Weimar C, Cotton D, Sha N, Sacco RL, Bath PM, Weber R, et al. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis. 2013;35(6):538–43.

    Article  CAS  PubMed  Google Scholar 

  88. Gaudino M, Benesch C, Bakaeen F, DeAnda A, Fremes SE, Glance L, et al. Considerations for reduction of risk of perioperative stroke in adult patients undergoing cardiac and thoracic aortic operations: a scientific statement from the American Heart Association. Circulation. 2020;142(14):e193–209.

    Article  PubMed  Google Scholar 

  89. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370(16):1494–503.

    Article  CAS  PubMed  Google Scholar 

  90. Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6–46.

    Article  CAS  PubMed  Google Scholar 

  91. Cai TQ, Wickham LA, Sitko G, Michener MS, Raubertas R, Handt L, et al. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. Eur J Pharmacol. 2015;758:107–14.

    Article  CAS  PubMed  Google Scholar 

  92. Flordal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg. 1993;80(6):723–4.

    Article  CAS  PubMed  Google Scholar 

  93. Leithäuser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39(1–4):293–302.

    Article  PubMed  Google Scholar 

  94. Armstrong MJ, Gronseth G, Anderson DC, Biller J, Cucchiara B, Dafer R, et al. Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;80(22):2065–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic College of Medicine and Science, 1221 Whipple St, Eau Claire, WI, 54703, USA

    Bayan Moustafa

  2. College of Medicine, University of Illinois at Chicago, 912 S Wood St, Chicago, IL, 60612, USA

    Fernando D. Testai

Authors
  1. Bayan Moustafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernando D. Testai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bayan Moustafa.

Ethics declarations

Conflict of Interest

Dr. Testai reports receiving private donation from Louis and Christine Friedrich.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Stroke

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moustafa, B., Testai, F.D. Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. Curr Neurol Neurosci Rep 22, 789–802 (2022). https://doi.org/10.1007/s11910-022-01237-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-022-01237-z

Keywords

Search

Navigation